Universität zu Köln

Sitnilska, Vasilena ORCID: 0000-0002-0886-4263, Schiller, Petra ORCID: 0000-0002-9957-1465, Krohne, Tim U. ORCID: 0000-0003-2280-925X and Altay, Lebriz ORCID: 0000-0003-1088-3786 (2024). Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy. BMC Ophthalmology, 24 (1). pp. 1-9. Springer Nature. ISSN 1471-2415

PDF s12886-023-03274-9.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution. Download (1MB)

Abstract

[Artikel-Nr.: 8] Background: To compare real-life anatomical and functional outcomes of half-dose photodynamic therapy (HD-PDT) and 577 nm subthreshold pulse laser therapy (SPL) in treatment-naïve patients with central serous chorioretinopathy (CSC). Methods: We retrospectively reviewed consecutive treatment-naïve CSC patients with non-resolving subretinal fluid (SRF) for more than 2 months who received either HD-PDT or SPL treatment. One repetition of the same treatment was allowed in patients with persistent SRF after first treatment. Functional and anatomical outcomes were assessed after first treatment and at final visit. Results: We included 95 patients (HD-PDT group, n = 49; SPL group, n = 46). Complete resolution of SRF after a single treatment was observed in 42.9% of HD-PDT-treated patients (n = 21; median time to resolution 7.1 weeks) and in 41.3% of SPL-treated patients (n = 19; median time to resolution 7.0 weeks). In the HD-PDT-group, 44.9% of patients (n = 22) and in the SPL-group, 43.5% (n = 20) of patients, received a second treatment due to persistent SRF, while 12.2% (n = 6) and 15.2% (n = 7), respectively, opted against a second treatment despite persistent SRF. After the final treatment, complete SRF resolution was observed in 61.2% of all HD-PDT-treated patients (n = 30; median time to resolution 8.8 weeks) and 60.9% of all SPL-treated patients (n = 28; median time to resolution 13.7 weeks, p = 0.876). In the final visit, both groups showed significant improvement of BCVA in comparison to baseline ( p < 0.001 for all). The change in BCVA from baseline to final visit was similar for the two groups (HD-PDT, median BCVA change 0.10 logMAR (IQR: 0.0-0.2); in SPL group, median BCVA change 0.10 logMAR (IQR: 0.0-0.2), P = 0.344). The CSC subclassification (simple versus complex) had no influence on the anatomical or functional outcome. Conclusions: High-density 577 nm SPL resulted in as good anatomical and functional treatment as HD-PDT and may thus represent a treatment alternative to HD-PDT in CSC.

Item Type:	Article
Creators:	Creators Email ORCID ORCID Put Code Sitnilska, Vasilena UNSPECIFIED https://orcid.org/0000-0002-0886-4263 UNSPECIFIED Schiller, Petra UNSPECIFIED https://orcid.org/0000-0002-9957-1465 UNSPECIFIED Krohne, Tim U. UNSPECIFIED https://orcid.org/0000-0003-2280-925X UNSPECIFIED Altay, Lebriz UNSPECIFIED https://orcid.org/0000-0003-1088-3786 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-814976
Identification Number:	10.1186/s12886-023-03274-9
Journal or Publication Title:	BMC Ophthalmology
Volume:	24
Number:	1
Page Range:	pp. 1-9
Number of Pages:	9
Date:	4 January 2024
Publisher:	Springer Nature
ISSN:	1471-2415
Language:	English
Faculty:	Faculty of Medicine
Divisions:	Faculty of Medicine > Augenheilkunde > Klinik und Poliklinik für Allgemeine Augenheilkunde Faculty of Medicine > Medizinische Statistik und Bioinformatik > Institut für Medizinische Statistik und Bioinformatik � IMSB
Subjects:	Life sciences Medical sciences Medicine
Uncontrolled Keywords:	Keywords Language Central serous chorioretinopathy ; Half-dose photodynamic therapy ; Prognostic factors ; Subliminal laser English
['eprint_fieldname_oa_funders' not defined]:	Publikationsfonds UzK
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/81497